HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

TT-232: a somatostatin structural derivative as a potent antitumor drug candidate.

Abstract
TT-232 (D-Phe-Cys-Tyr-D-Trp-Lys-Cys-Thr-NH2) has been developed as an antitumor somatostatin analog. TT-232 has no growth hormone release inhibitory effect and does not inhibit the secretion of gastric acid. This analog induces apoptosis in and exerts pronounced antiproliferative effects on various human tumors (colon, pancreas, lymphoma, leukemia, melanoma, hepatoma) cell lines. The growth of human xenografts (prostate, breast carcinoma, lymphoma, melanoma) and animal tumors (colon-26, P-388, S-180, B16, MXT) was inhibited by TT-232 (dose range: 30-750 microg/kg/day) in 54-98% of cases. Continuous long-term infusion proved to be the most effective way of administration. TT-232 combined with decarbazine or etoposide treatment enhanced the antitumor activity of these drugs on human melanoma and lymphoma xenografts, respectively. Regarding the mode of action, TT-232 activates cell cycle inhibitors via SSTR receptors, inhibits tyrosine kinases through interfering with the proliferative signaling cascades, and interacts with an intracellular receptor and an enzyme involved in glycolysis causing translocation of this enzyme to the nucleus, thus inducing apoptosis. TT-232 may be a promising candidate in the therapy of human malignancies.
AuthorsB Szende, Gy Kéri
JournalAnti-cancer drugs (Anticancer Drugs) Vol. 14 Issue 8 Pg. 585-8 (Sep 2003) ISSN: 0959-4973 [Print] England
PMID14501379 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • Antineoplastic Agents
  • Peptides, Cyclic
  • TT2-32
  • Somatostatin
  • Etoposide
  • Dacarbazine
Topics
  • Animals
  • Antineoplastic Agents (administration & dosage, pharmacology)
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Apoptosis
  • Cell Line, Tumor
  • Dacarbazine (administration & dosage)
  • Etoposide (administration & dosage)
  • Humans
  • Neoplasms (drug therapy, pathology)
  • Peptides, Cyclic (administration & dosage, pharmacology)
  • Somatostatin (administration & dosage, analogs & derivatives, pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: